The most promising results in the treatment of advanced HCC have been obtained with ICIs, which target programmed cell death (PD) receptor on T-cells or its ligands (programmed death ligand 1 and 2, PD-L1 and PD-L2) on cancer cells. Here, CD274 is linked to hepatocellular carcinoma.